This HTML5 document contains 85 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00757/identifier/chemspider/
n8http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00757/identifier/wikipedia/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00757/identifier/pharmgkb/
n27http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB00757/identifier/kegg-compound/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00757/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/patent/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00757/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n25http://linked.opendata.cz/resource/drugbank/medicinal-product/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00757/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n10http://www.drugs.com/cdi/
n13http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00757/identifier/national-drug-code-directory/
n18http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00757
rdf:type
n3:Drug
n3:description
Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
n3:dosage
n6:271B594E-363D-11E5-9242-09173F13E4C5 n6:271B594F-363D-11E5-9242-09173F13E4C5 n6:271B594C-363D-11E5-9242-09173F13E4C5 n6:271B594D-363D-11E5-9242-09173F13E4C5 n6:271B5950-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Balfour JA, Goa KL: Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs. 1997 Aug;54(2):273-98. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9257083 # Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9506240 # Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15740177
n3:group
approved
n3:halfLife
8.1 hours
n3:indication
For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy. Also used for the prevention of postoperative nausea and vomiting. This drug can be used intravenously for the treatment of postoperative nausea and vomiting.
n3:manufacturer
n5:271B5946-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00757 n27:DB00757
dcterms:title
Dolasetron
adms:identifier
n15:54666 n16:DB00757 n20:60654 n21:46505209 n22:0088-1208-06 n23:PA449390 n24:C07866 n26:Dolasetron
n3:mechanismOfAction
Dolasetron is a selective serotonin 5-HT<sub>3</sub> receptor antagonist. In vivo, the drug is rapidly converted into its major active metabolite, hydrodolasetron, which seems to be largely responsible for the drug's pharmacological activity. The antiemetic activity of the drug is brought about through the inhibition of 5-HT<sub>3</sub> receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT<sub>3</sub> receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.
n3:packager
n5:271B5941-363D-11E5-9242-09173F13E4C5 n5:271B5942-363D-11E5-9242-09173F13E4C5 n5:271B593F-363D-11E5-9242-09173F13E4C5 n5:271B5940-363D-11E5-9242-09173F13E4C5 n5:271B5944-363D-11E5-9242-09173F13E4C5 n5:271B5945-363D-11E5-9242-09173F13E4C5 n5:271B5943-363D-11E5-9242-09173F13E4C5
n3:patent
n19:4906755 n19:1329203
n3:routeOfElimination
Hydrodolasetron is eliminated by multiple routes, including renal excretion and, after metabolism, mainly glucuronidation, and hydroxylation.
n3:synonym
Dolasetron Dolasetronum Dolasétron
n3:volumeOfDistribution
* 5.8 L/kg [adults]
n7:hasAHFSCode
n8:56-22-20
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
69-77%
n3:salt
n3:synthesisReference
Janos Hajko, Tivadar Tamas, Adrienne Kovacsne-Mezei, Erika Molnarne, Csaba Peto, Csaba Szabo, "Production of dolasetron." U.S. Patent US20070203219, issued August 30, 2007.
foaf:page
n10:dolasetron.html n13:dolaset.htm
n3:IUPAC-Name
n4:271B5955-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B595B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B595A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5957-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5958-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5959-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B596B-363D-11E5-9242-09173F13E4C5 n4:271B5953-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B596D-363D-11E5-9242-09173F13E4C5 n4:271B5951-363D-11E5-9242-09173F13E4C5 n4:271B5954-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5952-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n18:A04AA04
n3:H-Bond-Acceptor-Count
n4:271B5961-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5962-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B595C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B595D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B595F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B595E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5960-363D-11E5-9242-09173F13E4C5
n3:absorption
Orally-administered dolasetron is well absorbed
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
115956-12-2
n3:category
n3:clearance
* Apparent cl=9.4 mL/min/kg [Healthy volunteers with IV treatment dose up to 5 mg/kg]
n3:containedIn
n25:271B594B-363D-11E5-9242-09173F13E4C5 n25:271B594A-363D-11E5-9242-09173F13E4C5 n25:271B5949-363D-11E5-9242-09173F13E4C5 n25:271B5947-363D-11E5-9242-09173F13E4C5 n25:271B5948-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5967-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5969-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B596A-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B596C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5966-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5965-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5968-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5956-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5963-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5964-363D-11E5-9242-09173F13E4C5